Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

Postgraduate Medicine

Volumn 123, Issue 2, 2011, Pages 169-176

  Wigal, Timothy ^a   Brams, Matthew ^b   Gasior, Maria ^c   Gao, Joseph ^c   Giblin, John ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SHIRE   (United States)

^d Clinical Study Centers LLC   (United States)

Author keywords

ADHD; Amphetamine; LDX; Lisdexamfetamine dimesylate; Stimulant; Vyvanse

Indexed keywords

LISDEXAMFETAMINE; LONG ACTING DRUG; PLACEBO;

ADULT; ANXIETY; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EFFECT SIZE; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; OPEN STUDY; OPTIMAL DRUG DOSE; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; SIMULATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; WORK ENVIRONMENT; WORKPLACE; XEROSTOMIA;

EID: 79955086456     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.03.2275     Document Type: Article

References (36)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
2. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
3. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry. 2002;63(suppl 12):29-35.
4. Gallagher R, Blader J. The diagnosis and neuropsychological assessment of adult attention deficit/hyperactivity disorder. Scientific study and practical guidelines. Ann N Y Acad Sci. 2001;931:148-171.
5. Adler L, Shaw D, Sitt D, Maya E, Morrill MI. Issues in the diagnosis and treatment of adult ADHD by primary care physicians. Prim Psychiatry. 2009;16(5):57-63.
6. Baron D. The impact of comorbid disorders on adults with ADHD. Psychiatr Times. 2007;(suppl 2):7-10.
7. Goodman DW. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract. 2007;13(5):318-327.
8. Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol. 2010;25(3):157-173.
9. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540.
10. Greenfield B, Hechman L. Treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5(1):107-121.
11. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-247.
12. Faraone SV. Interpreting estimates of treatment effects. Implications for managed care. P & T. 2008;33(12):700-701.
13. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24-29.
14. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-763.
15. Cohen J. Quantitative methods in psychology: a power primer. Psychol Bull. 1992;112(1):155-159.
16. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P&T. 2009;34(12):678-694.
17. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892-1908.
18. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327.
19. Adler LA, Goodman DW, Kollins SH, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373.
20. Wigal SB, Kollins SH, Childress AC, Adeyi B. Efficacy and tolerability of Lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatry Ment Health. 2010;4(1):32.
21. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct. 2010;6:34.
22. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10(1):92-111.
23. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:85-93.
24. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press. 1998;251.
25. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5(2):107-115.
26. Brams M, Moon E, Pucci M, Lopez FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010;26(8):1809-1825.
27. Adler LA, Spencer TJ, Biederman J, et al. The internal consistency and validity of the attention-deficit/hyperactivity disorder rating scale (ADHD-RS) with adult ADHD prompts as assessed during a clinical treatment trial. J ADHD Relate Disord. 2009;1(1):14-24.
28. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404.
29. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med. 2002;21(15):2131-2144.
30. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639.
31. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120-129.
32. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
33. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
34. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(2):268-277.
35. Young J, Mattingly G, Weisler R, et al. Response and symptomatic remission in a long-term trial of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: American Psychiatric Association's 162nd Annual Meeting; May 16-21, 2009; San Francisco, CA.
36. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168-179.